Literature DB >> 26743497

CD4+ and CD8+ T Cell Activation in Children with Hepatitis C.

Melissa A Sheiko1, Lucy Golden-Mason2, Silvia Giugliano2, Christine Waasdorp Hurtado1, Cara L Mack1, Michael R Narkewicz1, Hugo R Rosen3.   

Abstract

OBJECTIVES: To assess if peripheral T cell populations in children with chronic hepatitis C virus (HCV) infection would show evidence of activation/exhaustion and an attenuated functional response. STUDY
DESIGN: Compared with adults, children with HCV infection have a higher rate of spontaneous viral clearance. In adults, chronic HCV has been linked to T cell exhaustion. Little is known of the immune status of children with HCV. Peripheral blood mononuclear cells were isolated from 16 children with HCV (6 males, 10 females; mean age 8.6 years, range 2-17), 16 age- and sex-matched control children without HCV infection, and 20 adults with chronic HCV. Multiparameter flow cytometry was performed to characterize T cell differences across the 3 groups.
RESULTS: Controls and children with HCV had similar levels of CD4(+), CD8(+), and γδ(+) T cells. Children with HCV demonstrated a decrease in naïve T cells compared with control children and increased activation/exhaustion marker expression on both CD8(+) and CD4(+) T cells. Transcription factor analysis suggested functional activation of T cells in children with HCV; however, only the CD4(+) subset had enhanced cytokine production (interferon gamma and interleukin-2) compared with control children.
CONCLUSIONS: The HCV response in children is characterized by several changes in T cell phenotype. Many of these changes, such as increased T cell expression of programmed cell death-1, are similar to responses in adults. Of note, cytokine production by CD4(+) helper T cells is increased in children with HCV compared with age- and sex-matched control children, which may influence long-term prognosis in children with HCV.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26743497      PMCID: PMC4833455          DOI: 10.1016/j.jpeds.2015.11.055

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  43 in total

1.  Significance of alterations in PBMC immunophenotype of children with chronic viral hepatitis C-- the role of dendritic cells.

Authors:  I Mozer-Lisewska; G Dworacki; E Kaczmarek; W Sluzewski; M Kaczmarek; A Woźniak; J Zeromski
Journal:  Scand J Immunol       Date:  2006-04       Impact factor: 3.487

2.  Hepatitis C virus infects T cells and affects interferon-gamma signaling in T cell lines.

Authors:  Yasuteru Kondo; Vicky M H Sung; Keigo Machida; Minyi Liu; Michael M C Lai
Journal:  Virology       Date:  2006-12-18       Impact factor: 3.616

3.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.

Authors:  M Vogt; T Lang; G Frösner; C Klingler; A F Sendl; A Zeller; B Wiebecke; B Langer; H Meisner; J Hess
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

4.  T-Cell immune activation in children with vertically transmitted hepatitis C virus infection.

Authors:  A Giovannetti; F Mazzetta; R Coviello; A M Casadei; M R Sartorerri; M Marziali; M Pierdominici; D Kuonen; A M Pesce; M Fiorilli; F Aiuti; I Quinti
Journal:  Viral Immunol       Date:  2001       Impact factor: 2.257

5.  Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.

Authors:  Nicole Joller; Jason P Hafler; Boel Brynedal; Nasim Kassam; Silvia Spoerl; Steven D Levin; Arlene H Sharpe; Vijay K Kuchroo
Journal:  J Immunol       Date:  2011-01-03       Impact factor: 5.422

6.  Chronic hepatitis C in childhood: an 18-year experience.

Authors:  Raffaele Iorio; Antonietta Giannattasio; Angela Sepe; Luigi Maria Terracciano; Raffaella Vecchione; Angela Vegnente
Journal:  Clin Infect Dis       Date:  2005-09-30       Impact factor: 9.079

7.  Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients.

Authors:  C García-Monzón; P Jara; M Fernández-Bermejo; L Hierro; E Frauca; C Camarena; C Díaz; A De la Vega; J Larrauri; C García-Iglesias; M J Borque; P Sanz; L García-Buey; J A Moreno-Monteagudo; R Moreno-Otero
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

8.  Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease.

Authors:  Flavia Bortolotti; Gabriella Verucchi; Calogero Cammà; Giuseppe Cabibbo; Lucia Zancan; Giuseppe Indolfi; Raffaella Giacchino; Matilde Marcellini; Maria Grazia Marazzi; Cristiana Barbera; Giuseppe Maggiore; Pietro Vajro; Samuela Bartolacci; Fiorella Balli; Anna Maccabruni; Maria Guido
Journal:  Gastroenterology       Date:  2008-03-02       Impact factor: 22.682

9.  Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences.

Authors:  Lucy Golden-Mason; Jared Klarquist; Abdus S Wahed; Hugo R Rosen
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

10.  The natural history of hepatitis C virus (HCV) infection.

Authors:  Stephen L Chen; Timothy R Morgan
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

View more
  3 in total

Review 1.  Hepatitis C virus infection in children and adolescents.

Authors:  James E Squires; William F Balistreri
Journal:  Hepatol Commun       Date:  2017-03-23

2.  Immune Activation Induces Telomeric DNA Damage and Promotes Short-Lived Effector T Cell Differentiation in Chronic HCV Infection.

Authors:  Lam Nhat Nguyen; Lam Ngoc Thao Nguyen; Juan Zhao; Madison Schank; Xindi Dang; Dechao Cao; Sushant Khanal; Bal Krishna Chand Thakuri; Jinyu Zhang; Zeyuan Lu; Xiao Y Wu; Mohamed El Gazzar; Shunbin Ning; Ling Wang; Jonathan P Moorman; Zhi Q Yao
Journal:  Hepatology       Date:  2021-08-25       Impact factor: 17.425

3.  Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19.

Authors:  Estéfani García-Ríos; Alejandra Leivas; Francisco J Mancebo; Laura Sánchez-Vega; Diego Lanzarot; José María Aguado; Joaquín Martínez-López; María Liz Paciello; Pilar Pérez-Romero
Journal:  Biomedicines       Date:  2022-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.